PTIX Protagenic Therapeutics, Inc.
Company Updates ·
The FDA raised no objection to the planned Phase 1 design and identified no clinical hold issues. Protagenic plans to submit the IND before the end of 2026.
The board notified Alexander Arrow, MD, on March 31, 2026, that his employment will be terminated effective April 30, 2026. The filing gives no reason for the decision.
Protagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring.
Phytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets.
Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide. In preclinical animal models, PT00114 has shown efficacy in depression, anxiety, substance abuse and addiction, and PTSD. The company holds exclusive worldwide rights to PT00114 through a license agreement with the University of Toronto. Its first human trial began on September 26, 2023, and the multiple-dose portion of the Phase I study in healthy volunteers has been completed. Protagenic expects to begin a Phase 2 study in late 2026 in a targeted population of patients with chronic stress-related psychiatric disorders. It is also developing follow-on compounds in the TCAP family. Its earlier Phytanix Bio reverse merger was unwound during the year ended March 31, 2026. Programs from that prior business include PHYX-003, an anti-obesity candidate, and PHYX-004, a cannabis-derived extract for bladder pain syndrome and interstitial cystitis, both in preclinical development.
| Product or program | What it is | Stage |
|---|---|---|
| PT00114 | Synthetic TCAP-1 peptide for stress-related neuropsychiatric and mood disorders | Phase I multiple-dose portion completed; Phase 2 expected late 2026 |
| PHYX-003 | Anti-obesity candidate from the prior Phytanix Bio business | Preclinical |
| PHYX-004 | Cannabis-derived extract for bladder pain syndrome and interstitial cystitis | Preclinical development |
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $901,896 | $376,740 |
| Net income (loss) | $1.4 million | -$3.6 million |
| Cash from operations | -$2.8 million | -$1.8 million |
| Cash and equivalents | $1.5 million | $14,531 |
Protagenic Therapeutics, Inc. trades under the ticker PTIX on OTC.
Protagenic Therapeutics, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Protagenic Therapeutics, Inc. is 1022899. Its filings are on SEC EDGAR.
1,810,208 shares as of 2026-08-19, per the cover page of its 10-Q filed 2026-08-19.
Our directory records Protagenic Therapeutics, Inc. under United States.
Our directory classifies Protagenic Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Protagenic Therapeutics, Inc. is US74365N3017.
aibio.space lists Protagenic Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide.
PT00114: Synthetic TCAP-1 peptide for stress-related neuropsychiatric and mood disorders Stage: Phase I multiple-dose portion completed; Phase 2 expected late 2026.
PHYX-003: Anti-obesity candidate from the prior Phytanix Bio business Stage: Preclinical.
$0 for the fiscal year ended Mar 31, 2026, as reported to the SEC.
Protagenic Therapeutics, Inc. reported net income of $1.4 million for the fiscal year ended Mar 31, 2026, and used $2.8 million of cash in operations, per its annual report to the SEC.
$901,896 in the fiscal year ended Mar 31, 2026, per its annual report.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,4.01,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,5.03,8.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio